$CETX is currently undervalued as $CETX Cemtrex

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
68
$CETX is currently undervalued as $CETX Cemtrex (NASDAQ:CETX), a commercial services company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM over the last few months, increasing to $2.93 at one point.

This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether Cemtrex’s current trading price of $2.17 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Cemtrex’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

What is Cemtrex worth?

Good news, investors! Cemtrex is still a bargain right now. I’ve used the price-to-equity ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 8.89x is currently well-below the industry average of 18.03x, meaning that it is trading at a cheaper price relative to its peers. However, given that Cemtrex’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What kind of growth will Cemtrex generate?

NasdaqCM:CETX Future Profit

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company’s future expectations. Though in the case of Cemtrex, it is expected to deliver on earnings growth in the upcoming, which should help build up its investment thesis. It appears that risk of future uncertainty is low in the near term.

What this means for you:

Are you a shareholder? Although CETX is currently undervalued, the negative outlook does bring on some uncertainty, which equates to higher risk. I recommend you think about whether you want to increase your portfolio exposure to CETX for a good return.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading